Use of Linomide to increase hemopoietic cell precursors

Abstract

The present invention concerns the use of Linomide, i.e. N-phenyl-N-methyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide for the treatment of humans subjected to BMT, cytostatic treatment irradiations or combinations thereof.

We claim: 
     
       1. A method for increasing the frequency of bone marrow NK cell precursors comprising administering to a patient a therapeutically effective dose of N-phenyl-N-methyl-1,2 dihydro-4 hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide or an acceptable salt thereof. 
     
     
       2. The method of claim 1, wherein administration is oral. 
     
     
       3. The method of claim 2, wherein the administration is parenteral. 
     
     
       4. The method of claim 1, wherein the administration is by injection. 
     
     
       5. The method of claim 1, wherein the therapeutically effective amount ranges from 0.01 to 10.0 mg/kg body weight. 
     
     
       6. The method of claim 1, wherein the therapeutically effective amount ranges from 0.05 to 1.0 mg/kg body weight. 
     
     
       7. The of claim 1, wherein the therapeutically effective amount ranges from 0.2 to 0.3 mg/kg body weight. 
     
     
       8. The method claim 1, wherein the administration is daily for an effective period. 
     
     
       9. The method of claim 1, wherein the administration is bi-weekly for an effective period. 
     
     
       10. The method of claim 1, wherein the administration is bi-monthly for an effective period. 
     
     
       11. The method of claim 1, wherein the effective dose is dispersed within a pharmaceutically acceptable carrier. 
     
     
       12. A method for accelerating bone marrow cell recovery after bone marrow transplantation comprising administering to a patient who as received a bone marrow transplant a therapeutically effective dose of N-phenyl-N-methyl-1,2 dihydro-4 hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide or an acceptable salt thereof, which therapeutically effective dose increases the frequency of bone marrow NK cell precursors. 
     
     
       13. A method for accelerating bone marrow recovery from anti-neoplastic drug treatment comprising: administering to a patient who has received anti-neoplastic drug treatment which is toxic to hemopoietic cells, a therapeutically effective dose of N-phenyl-N-methyl-1,2 dihydro-4 hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide or an acceptable salt thereof, which therapeutically effective dose increases the frequency of bone marrow NK cell precursors.   
     
     
       14. A method for accelerating bone marrow recovery from irradiation treatment comprising administering to a patient who has received irradiation treatment which significantly impairs hemopoietic cells, a therapeutically effective dose of N-phenyl-N-methyl-1,2 dihydro-4 hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide or an acceptable salt thereof, which therapeutically effective dose increases the frequency of bone marrow NK cell precursors.